220 related articles for article (PubMed ID: 23693152)
1. UNC1062, a new and potent Mer inhibitor.
Liu J; Zhang W; Stashko MA; Deryckere D; Cummings CT; Hunter D; Yang C; Jayakody CN; Cheng N; Simpson C; Norris-Drouin J; Sather S; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
Eur J Med Chem; 2013 Jul; 65():83-93. PubMed ID: 23693152
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
[TBL] [Abstract][Full Text] [Related]
3. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Zhang W; DeRyckere D; Hunter D; Liu J; Stashko MA; Minson KA; Cummings CT; Lee M; Glaros TG; Newton DL; Sather S; Zhang D; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2014 Aug; 57(16):7031-41. PubMed ID: 25068800
[TBL] [Abstract][Full Text] [Related]
4. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.
Zhang W; Zhang D; Stashko MA; DeRyckere D; Hunter D; Kireev D; Miley MJ; Cummings C; Lee M; Norris-Drouin J; Stewart WM; Sather S; Zhou Y; Kirkpatrick G; Machius M; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2013 Dec; 56(23):9683-92. PubMed ID: 24195762
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
Baladi T; Aziz J; Dufour F; Abet V; Stoven V; Radvanyi F; Poyer F; Wu TD; Guerquin-Kern JL; Bernard-Pierrot I; Garrido SM; Piguel S
Bioorg Med Chem; 2018 Nov; 26(20):5510-5530. PubMed ID: 30309671
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.
Zhang W; McIver AL; Stashko MA; DeRyckere D; Branchford BR; Hunter D; Kireev D; Miley MJ; Norris-Drouin J; Stewart WM; Lee M; Sather S; Zhou Y; Di Paola JA; Machius M; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2013 Dec; 56(23):9693-700. PubMed ID: 24219778
[TBL] [Abstract][Full Text] [Related]
7. Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells.
Koda Y; Itoh M; Tohda S
Anticancer Res; 2018 Jan; 38(1):199-204. PubMed ID: 29277773
[TBL] [Abstract][Full Text] [Related]
8. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
Christoph S; Deryckere D; Schlegel J; Frazer JK; Batchelor LA; Trakhimets AY; Sather S; Hunter DM; Cummings CT; Liu J; Yang C; Kireev D; Simpson C; Norris-Drouin J; Hull-Ryde EA; Janzen WP; Johnson GL; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2013 Nov; 12(11):2367-77. PubMed ID: 23997116
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
Szabadkai I; Torka R; Garamvölgyi R; Baska F; Gyulavári P; Boros S; Illyés E; Choidas A; Ullrich A; Őrfi L
J Med Chem; 2018 Jul; 61(14):6277-6292. PubMed ID: 29928803
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent and selective Axl inhibitor in preclinical model.
Inoue S; Yamane Y; Tsukamoto S; Azuma H; Nagao S; Murai N; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem; 2021 Jun; 39():116137. PubMed ID: 33930844
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for selective small molecule kinase inhibition of activated c-Met.
Rickert KW; Patel SB; Allison TJ; Byrne NJ; Darke PL; Ford RE; Guerin DJ; Hall DL; Kornienko M; Lu J; Munshi SK; Reid JC; Shipman JM; Stanton EF; Wilson KJ; Young JR; Soisson SM; Lumb KJ
J Biol Chem; 2011 Apr; 286(13):11218-25. PubMed ID: 21247903
[TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
[TBL] [Abstract][Full Text] [Related]
14. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
[TBL] [Abstract][Full Text] [Related]
16. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
19. Efficient Arylation of 2,7-Naphthyridin-1(2
Wang MS; Xu HC; Gong Y; Qu RY; Zhuo LS; Huang W
ACS Comb Sci; 2020 Sep; 22(9):457-467. PubMed ID: 32589005
[TBL] [Abstract][Full Text] [Related]
20. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.
Cummings CT; Linger RM; Cohen RA; Sather S; Kirkpatrick GD; Davies KD; DeRyckere D; Earp HS; Graham DK
Oncotarget; 2014 Nov; 5(21):10434-45. PubMed ID: 25372020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
